Zacks Investment Research Upgrades Clinigen Group (CLIGF) to Hold

Zacks Investment Research upgraded shares of Clinigen Group (OTCMKTS:CLIGF) from a sell rating to a hold rating in a research report report published on Thursday morning, reports.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

OTCMKTS CLIGF remained flat at $$12.90 during trading hours on Thursday. 600 shares of the company’s stock were exchanged. Clinigen Group has a 12-month low of $9.87 and a 12-month high of $12.90.

See Also: Marijuana Stocks

Get a free copy of the Zacks research report on Clinigen Group (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.